Definitive Contract 75N91022C00059

This federal contract award was issued by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the Cancer Hospital, Chinese Academy Of Medical Sciences. The contract, which is a definitive contract with a firm fixed price, is for "UPPER GASTROINTESTINAL CANCER PREVENTION STUDIES" and has a period of performance from September 20, 2017 to September 19, 2018. The potential value of the contract is $398,291.00, and the completion date...

The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a $120,000.00 firm fixed price purchase order contract to The Chinese University of Hong Kong, an Other Not For Profit Organization, to recruit breast cancer patients and collect clinical and epidemiologic data and biospecimens. This contract does not have a set-aside designation. The Chinese University of Hong Kong has received three prior prime federal contract awards from the...

This is a $114,966.00 firm-fixed-price purchase order awarded by the Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI) to Gene Square Bio-Technology LTD, a for-profit limited liability company based in China. The contract is for genetic studies of myeloid and lymphoid malignancy in China in support of NCI's Division of Cancer Epidemiology and Genetics. The work will involve scanning 2,129 DNA samples from the NCI's AsiaLymph study...

<p>This is a definitive cost-no-fee contract awarded by the National Cancer Institute, a civilian agency, to Georgetown University Inc. on September 15, 1992. The contract, valued at $540,188,796.00, is for TAS PLCO/NLST FY2010 FUNDING and has a completion date of January 31, 2012. The contract does not have a set-aside designation. The National Cancer Institute is the funding agency for this award, which is likely related to the agency's cancer research and clinical trials programs.</p>

This $17,053.58 firm fixed price purchase order was awarded by the National Cancer Institute (NCI), a civilian agency, to an undisclosed prime contractor on September 11, 2024. The contract is for a service agreement with a period of performance through March 10, 2025. No set-aside designation is indicated. The contract award does not provide details about the specific products or services to be delivered, but as the NCI is the funding agency, the work is likely related to the institute's cancer...

This is a firm fixed price purchase order contract awarded by the National Institutes of Health (NIH), National Cancer Institute (NCI) to Bevital AS, a foreign-owned for-profit organization. The contract supports the Department of Health and Human Services (HHS), NIH, NCI, Division of Cancer Epidemiology and Genetics (DCEG), Metabolic Epidemiology Branch (MEB) in the area of one-carbon metabolism (OCM) biomarkers and upper gastrointestinal cancers in the Golestan Cohort Study. The contract has a...

This is a firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Digital Artefacts LLC, a minority-owned, small disadvantaged business. The contract is for the development of a &quot;CANCER PATIENT COGNITIVE ASSESSMENT PLATFORM&quot; under TOPIC 343, with a ceiling value of $216,431.00 and a completion date of September 18, 2017. The contract does not have a set-aside designation. As the NCI is the funding agency, this contract supports the...

<p>The National Cancer Institute (NCI) awarded a $20,000.00 firm fixed price purchase order contract to Lingxiao Wang, a self-certified small disadvantaged business, for professional services (non-federal services). The contract has an ultimate completion date of October 8, 2024 and was awarded on September 9, 2024. This contract is not associated with a larger vehicle and does not have a set-aside designation.</p>

<p>The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed-price purchase order to C S Bio Co., a Minority Owned Business, Subchapter S Corporation, for $18,175.00 in laboratory testing services. The contract has an anticipated completion date of August 31, 2024 and was awarded on April 1, 2024. The services will be performed in Bethesda, Maryland. No set-aside was used for this award.</p>

This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to the International Union Against Cancer (UICC), a non-profit organization. The purpose of this $542,725.00 definitive contract is to facilitate international scientific cooperation in cancer research through the exchange visits of scientists. The contract is not set-aside. It began on September 30, 2009 and is scheduled to be completed by September 29, 2014. The contract aims to promote the direct and...